BIOS Misses Earnings Mark But Rev Tops - Analyst Blog
09 Mai 2013 - 11:20AM
Zacks
In the first quarter of 2013,
BioScrip Inc. (BIOS) posted adjusted earnings per
share (EPS) of a penny, better than the year-ago adjusted loss of 2
cents. Nonetheless, the result missed the Zacks Consensus Estimate
by a couple of cents.
On a reported basis, BioScrip’s net loss from continuing operations
of $7.5 million or a loss of 13 cents per share was worse than the
net loss of $2 million or 4 cents per share in the year-ago
quarter. This was mainly due to a higher share count and margin
contraction in the quarter.
Total revenue rose 27.9% year over year to $199.1 million in the
first quarter, exceeding the Zacks Consensus Estimate of $189
million. In the first quarter, solid revenue growth was
attributable to contributions from Infusion Services and Home
Health Services business.
The company recorded a robust hike of 41.5% in Infusion Services
revenues to $154.4 million on the back of volume growth and
accretive acquisitions. Revenues from the Home Health Services
segment rose 7.4% to $17.9 million, led by volume growth from
private duty nursing activity. Lastly, revenues from the PBM
Services segment were $26.8 million, down 10.4% from the prior-year
quarter. The decline was due to lower sales volume of discount
cards.
While the cost of product revenues shot up 45.9% to $105.5 million,
the cost of service revenues inched up 1.7% to $30.3 million in the
quarter. Gross margin contracted 260 basis points (bps) to $31.8%
in the quarter due to unfavorable product mix. Selling, general and
administrative (SG&A) expenses increased 18.4% to $52.8
million. The gross margin contraction and surging SG&A resulted
in a 50 bps drag in adjusted operating margin in the quarter to
5.2%.
Exiting the first quarter, BioScrip had no cash balance compared
with $62.1 million in the sequentially prior quarter. The company’s
outstanding borrowings under its revolving credit facility was
roughly $28 million due to the HomeChoice takeover. Following the
first quarter, BioScrip raised net proceeds of $118.6 million from
secondary offering.
Outlook
For 2013, BioScrip continues to expect revenues of $830–$865
million, reflecting growth in the range of 25% to 30%. The current
Zacks Consensus Estimate is pegged at $839 million.
Our Take
BioScrip reported mixed results in the first quarter of 2013. While
top-line sailed past the Zacks Consensus Estimate, the bottom-line
was worse than expected. The Infusion services franchise appears to
be a major revenue driver for the company. Moreover, the recent
acquisitions are likely to accelerate growth in the future.
However, reimbursement cuts and adverse business mix leading to
margin pressure continues to drag the financial results for
BioScrip. Also worth mentioning is the tough competitive landscape
with larger players and deeper resources.
The stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for BioScrip, other stocks such as CVS
Caremark (CVS), Rite Aid Corporation
(RAD) and GNC Holdings Inc. (GNC) warrant a look.
These stocks carry a Zacks Rank #2 (Buy).
BIOSCRIP INC (BIOS): Free Stock Analysis Report
CVS CAREMARK CP (CVS): Free Stock Analysis Report
GNC HOLDINGS (GNC): Free Stock Analysis Report
RITE AID CORP (RAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024